OptimizeRx (OPRX) Receivables - Other (2010 - 2026)

OptimizeRx's Receivables - Other history runs 11 years deep, the most recent figure standing at $4.7 million for Q1 2026.

• In Q1 2026, Receivables - Other rose 11.06% year-over-year to $4.7 million; the TTM figure through Mar 2026 stood at $4.7 million (up 11.06% YoY), while the FY2025 annual figure was $3.9 million, up 21.66% from the prior year.
• Receivables - Other came in at $4.7 million for Q1 2026 at OptimizeRx, up from $3.9 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $6.1 million in Q4 2023 to a low of $3.2 million in Q4 2024.
• A 5-year average of $4.3 million and a median of $3.9 million in 2025 frame the typical range for Receivables - Other.
• Across the five-year window, Receivables - Other jumped 69.73% in 2022 and tumbled 46.67% in 2024, its largest moves.
• OptimizeRx's Receivables - Other stood at $3.6 million in 2022, then soared by 69.62% to $6.1 million in 2023, then slumped by 46.67% to $3.2 million in 2024, then advanced by 21.66% to $3.9 million in 2025, then rose by 19.43% to $4.7 million in 2026.
• According to Business Quant data, Receivables - Other over the past three periods registered $4.7 million, $3.9 million, and $3.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison